Gilead Sciences will go to court this week to argue that it does not need to pay the US Government a share of the profits it has made on the use of its HIV drugs for pre-e
Gilead has won another victory in a wide-ranging lawsuit brought against clinics, prescribers, medical labs, and pharmacies it has accused of making fraudulent reimburseme
Gilead has won a crucial court order in a wide-ranging lawsuit against a network of clinics, prescribers, medical labs and pharmacies in Florida that it claims have been making fraudulent r
GlaxoSmithKline’s HIV joint venture ViiV Healthcare could mount a challenge to Gilead’s HIV pre-exposure prophylaxis (PrEP) medicines after the FDA granted Breakthrough Therapy Designation
A group of independent experts from Wales has become the latest to back Gilead’s Truvada as a way of slowing the spread of HIV, ahead of key decisions from Welsh and Scottish cost-effective
Japan’s Taisho Pharmaceutical looks like it could be heading into private ownership, thanks to a management buyout offer (MBO) that could value the company at almost $5 bi
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio